TACH101 Clinical Trial

Tachyon is currently conducting a Phase 1 open-label clinical study evaluating thesafety, tolerability, pharmacokinetics, and anti-tumor activity of TACH101, an investigational first-in-class inhibitor of KDM4, an epigenetic regulator, for the treatment of patients with advanced solid tumors.

For detailed information on the ongoing Phase 1 trial, please visit: clinicaltrials.gov.

Tachyon’s Commitment to Diversity

Expanded Access Policy (EAP)